<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-167918" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Pemetrexed</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ramos Morales</surname>
            <given-names>Iliana</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Yacobucci</surname>
            <given-names>Matthew J.</given-names>
          </name>
          <aff>Saint John Fisher College, Rochester, NY</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sheehy</surname>
            <given-names>Conor</given-names>
          </name>
          <aff>University of Washington</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Iliana Ramos Morales declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Matthew Yacobucci declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Conor Sheehy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>8</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-167918.s1" sec-type="Indications">
        <title>Indications</title>
        <p content-type="pubmed-excerpt">Pemetrexed is an antifolate metabolic inhibitor approved by the U.S. Food Drug Administration (FDA) in 2004 for the treatment of malignant pleural mesothelioma.<xref ref-type="bibr" rid="article-167918.r1">[1]</xref><xref ref-type="bibr" rid="article-167918.r2">[2]</xref>&#x000a0;Pemetrexed was developed by&#x000a0;Edward C. Taylor and his team at Princeton University, who&#x000a0;first synthesized&#x000a0;lometrexol, the prototypical <italic toggle="yes">de novo</italic> purine antimetabolite.<xref ref-type="bibr" rid="article-167918.r3">[3]</xref>&#x000a0;However, lometrexol's structure was unstable, requiring the&#x000a0;C-6 chiral center to be replaced with a pyrrolopyrimidine ring, creating a new molecule: N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid. Eli Lilly and Company brought this medication to the market and gave it a brand name.<xref ref-type="bibr" rid="article-167918.r4">[4]</xref>&#x000a0;Pemetrexed is an antineoplastic agent that can be given as a single agent or as part of combination therapy.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Malignant pleural mesothelioma&#x000a0;</bold><xref ref-type="bibr" rid="article-167918.r2">[2]</xref><xref ref-type="bibr" rid="article-167918.r5">[5]</xref><xref ref-type="bibr" rid="article-167918.r6">[6]</xref><xref ref-type="bibr" rid="article-167918.r7">[7]</xref>
<list list-type="bullet"><list-item><p>First-line treatment for stage I to stage IIIA, regardless of histologic type (as monotherapy)</p></list-item><list-item><p>First-line treatment for unresectable tumors, regardless of histologic type or patients who are not candidates for surgery (in combination with cisplatin)</p></list-item><list-item><p>As an adjuvant medication</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Non-small cell lung cancer (NSCLC), nonsquamous&#x000a0;</bold><xref ref-type="bibr" rid="article-167918.r8">[8]</xref><xref ref-type="bibr" rid="article-167918.r9">[9]</xref><xref ref-type="bibr" rid="article-167918.r10">[10]</xref><xref ref-type="bibr" rid="article-167918.r11">[11]</xref>
<list list-type="bullet"><list-item><p>Locally advanced or metastatic, nonsquamous NSCLC (in combination with cisplatin)</p></list-item><list-item><p>Metastatic, nonsquamous NSCLC in patients with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations (in combination with platinum chemotherapy and pembrolizumab)</p></list-item><list-item><p>Maintenance treatment in patients whose disease has not progressed after&#x000a0;4 cycles of platinum-based chemotherapy</p></list-item><list-item><p>Patients with a history of&#x000a0;prior chemotherapy (as monotherapy)</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Beyond its approved indications, pemetrexed has&#x000a0;demonstrated&#x000a0;effectiveness in treating other malignancies, highlighting its potential as a medication for managing challenging forms of cancer. Some of these are outlined below.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Metastatic bladder cancer: </bold>Pemetrexed is used as&#x000a0;monotherapy or&#x000a0;in combination with cisplatin for metastatic transitional-cell bladder cancer.<xref ref-type="bibr" rid="article-167918.r12">[12]</xref><xref ref-type="bibr" rid="article-167918.r13">[13]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Metastatic breast cancer: </bold>Pemetrexed is used as a first-line or second-line treatment for advanced or metastatic breast cancer.<xref ref-type="bibr" rid="article-167918.r14">[14]</xref><xref ref-type="bibr" rid="article-167918.r15">[15]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Recurrent cervical cancer:</bold> Pemetrexed may be administered as a second-line treatment for recurrent or persistent cervical cancer.<xref ref-type="bibr" rid="article-167918.r16">[16]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Recurrent ovarian cancer: </bold>Pemetrexed is considered for recurrent or persistent platinum-resistant therapy of ovarian or primary peritoneal carcinoma.<xref ref-type="bibr" rid="article-167918.r1">[1]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Metastatic thymic malignancies: </bold>Pemetrexed is utilized as&#x000a0;monotherapy in recurrent or metastatic thymoma or thymic carcinoma.<xref ref-type="bibr" rid="article-167918.r17">[17]</xref><xref ref-type="bibr" rid="article-167918.r18">[18]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-167918.s2" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Pemetrexed inhibits the folate-dependent metabolic processes necessary for cellular replication. Specifically, it targets enzymes responsible for DNA and RNA synthesis, including thymidylate synthase (TS), dihydrofolate reductase (DHFR), glycinamide ribonucleotide formyltransferase (GARFT), and aminoimidazole carboxamide ribonucleotide formyltransferase (AICARFT), which disrupts the synthesis of purines, pyrimidines, and proteins.<xref ref-type="bibr" rid="article-167918.r3">[3]</xref>&#x000a0;Pemetrexed is transported into cells via membrane carriers, where it is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. Polyglutamation is thought to occur&#x000a0;more often in tumor cells than non-tumor cells. Polyglutamated metabolites have an increased intracellular half-life and prolonged drug action.<xref ref-type="bibr" rid="article-167918.r19">[19]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>The pharmacokinetics of pemetrexed comprise rapid intravenous (IV) administration, significant plasma protein binding, and renal metabolism. A thorough understanding of these pharmacokinetic characteristics facilitates this medication's safe and productive use in cancer therapy. With this understanding, healthcare providers can tailor dosing schedules and adeptly&#x000a0;manage potential drug interactions or adverse reactions.<xref ref-type="bibr" rid="article-167918.r20">[20]</xref></p>
        <p><bold>Absorption: </bold>Pemetrexed is administered via intravenous (IV) formulation, bypassing the absorption phase. The IV infusion facilitates rapid and complete distribution of pemetrexed throughout the systemic circulation.</p>
        <p><bold>Distribution: </bold>Following IV administration<bold>, </bold>pemetrexed exhibits a steady-state volume of distribution of approximately 16.1 liters. Approximately 81% of the drug is bound to plasma proteins.</p>
        <p><bold>Metabolism:</bold> Pemetrexed is not metabolized to a significant extent.</p>
        <p><bold>Elimination:</bold> Pemetrexed is predominantly eliminated through renal excretion, with approximately 70% to 90% of the drug being excreted unchanged in the urine. In patients with consistent renal function, the total systemic clearance of pemetrexed is 91.8 mL/min, and its elimination half-life is approximately 3.5 hours.&#x000a0;Pemetrexed is a substrate for&#x000a0;organic anion transporter 3 (OAT3), a transporter protein primarily found in the kidney. This transporter is responsible for transporting pemetrexed from the bloodstream into renal tubular cells, facilitating its elimination from the body through urine.<xref ref-type="bibr" rid="article-167918.r21">[21]</xref></p>
      </sec>
      <sec id="article-167918.s3" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available&#x000a0;Forms and Strengths</bold>
</p>
        <p>Pemetrexed is available in 750 mg, 500 mg, 100 mg, and 1 mg formulations and may be administered intravenously in 25 mg/mL or 10 mg/mL concentrations.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>The typical pemetrexed dose&#x000a0;is 500 mg/m&#x000b2; every&#x000a0;3 weeks,&#x000a0;depending on the indication. The clinician should always consult the drug package insert and institutional protocols before designing a dosing regimen for any patient. Pemetrexed&#x000a0;is usually infused over 10&#x000a0;minutes, although this can vary depending on the specific indication or treatment protocol. When pemetrexed is part of a combination chemotherapy regimen, the exact administration order&#x000a0;varies based on the protocol. Therefore, it is crucial to consult a protocol to determine the recommended sequence.</p>
        <p>Before initiating pemetrexed therapy, it's recommended to start vitamin supplements to enhance their effectiveness and manage potential side effects. Premedication optimizes treatment outcomes while minimizing adverse effects, such as mucositis, gastrointestinal toxicity, and cutaneous reactions. Healthcare providers must monitor patients closely and adjust&#x000a0;therapy based on individual responses.<xref ref-type="bibr" rid="article-167918.r22">[22]</xref>&#x000a0;A standard premedication regimen is outlined below.&#x000a0;</p>
        <p>
<bold>&#x000a0;&#x000a0;&#x000a0; Folic acid:</bold>
</p>
        <p>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0; Dosage: 400 to 1,000 &#x003bc;g orally once daily</p>
        <p>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0; Start: 7 days before initiating pemetrexed therapy</p>
        <p>&#x000a0; &#x000a0; &#x000a0; &#x000a0; Duration: Throughout the treatment period and for 21 days after the final pemetrexed dose</p>
        <p>
<bold>&#x000a0;&#x000a0;&#x000a0; Vitamin B12:</bold>
</p>
        <p>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0; Dosage: 1,000 &#x003bc;g intramuscularly (IM) once</p>
        <p>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0; Start: Administer once 7 days before initiating treatment</p>
        <p>&#x000a0;Duration: Repeat every 3 therapy cycles</p>
        <p>&#x000a0;&#x000a0;&#x000a0; <bold>Dexamethasone:</bold></p>
        <p>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0; Dosage: 4 mg orally twice daily</p>
        <p>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0; Start:&#x000a0;24 hours before initiating pemetrexed therapy</p>
        <p>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0; Duration: Administer twice daily for 3 days&#x000a0;</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment: </bold>Pemetrexed does not have any dose adjustments. Asymptomatic elevations of aspartate transaminase, alanine transaminase, and total bilirubin were&#x000a0;observed&#x000a0;during clinical trials; however, this did not affect the dose or schedule of pemetrexed administration.<xref ref-type="bibr" rid="article-167918.r23">[23]</xref></p>
        <p><bold>Renal impairment: </bold>Pemetrexed may increase toxic exposure&#x000a0;in patients with kidney disease&#x000a0;due to reduced plasma clearance. The recommended dose&#x000a0;for a patient with&#x000a0;a creatinine clearance (CrCl) &#x02265;45 mL/min is 500 mg/m<sup>2</sup> on day 1 of each 21-day cycle until disease progression or unacceptable toxicity. Patients with a CrCl of 45 to 60 mL/min may be at increased risk of hematologic, gastrointestinal, and kidney-related toxicity.<xref ref-type="bibr" rid="article-167918.r24">[24]</xref>&#x000a0;Using pemetrexed in patients with CrCl &#x0003c;45 mL/min is not recommended. Although pemetrexed may be removed through dialysis, it is not recommended for these patients.<xref ref-type="bibr" rid="article-167918.r25">[25]</xref><xref ref-type="bibr" rid="article-167918.r26">[26]</xref><xref ref-type="bibr" rid="article-167918.r27">[27]</xref></p>
        <p><bold>Pregnancy considerations: </bold>Based on animal studies and its mechanism of action, pemetrexed is not recommended during pregnancy due to its risk of causing fetal harm.<xref ref-type="bibr" rid="article-167918.r27">[27]</xref></p>
        <p><bold>Breastfeeding considerations:</bold> The presence&#x000a0;or absence of pemetrexed in breast milk has not been established. Based on potential serious adverse effects, breastfeeding is not recommended during treatment and for 1 week after the last dose of pemetrexed.</p>
        <p><bold>Pediatric patients: </bold>The safety and efficacy of pemetrexed have not been established in pediatric patients.</p>
        <p><bold>Older patients:</bold> Clinical studies have revealed no differences&#x000a0;between patients older and younger than 65. Refer to adult dosage.<xref ref-type="bibr" rid="article-167918.r28">[28]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-167918.s4" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse effects associated with pemetrexed are primarily caused by dose-related toxicities. One of the most frequent adverse events is myelosuppression. Patients have a higher risk of myelosuppression if they are not&#x000a0;administered vitamin supplementation before, during, and after&#x000a0;undergoing pemetrexed therapy.<xref ref-type="bibr" rid="article-167918.r29">[29]</xref></p>
        <p>The following common adverse effects are categorized by system.<xref ref-type="bibr" rid="article-167918.r30">[30]</xref><xref ref-type="bibr" rid="article-167918.r31">[31]</xref></p>
        <p>
<bold>Hematology</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Anemia</p>
          </list-item>
          <list-item>
            <p>Neutropenia</p>
          </list-item>
          <list-item>
            <p>Thrombocytopenia</p>
          </list-item>
        </list>
        <p>
<bold>Generalized symptoms</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Fatigue</p>
          </list-item>
        </list>
        <p>
<bold>Gastrointestinal</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Nausea</p>
          </list-item>
          <list-item>
            <p>Vomiting</p>
          </list-item>
          <list-item>
            <p>Anorexia</p>
          </list-item>
          <list-item>
            <p>Constipation</p>
          </list-item>
          <list-item>
            <p>Mucositis</p>
          </list-item>
          <list-item>
            <p>Diarrhea</p>
          </list-item>
          <list-item>
            <p>Heartburn</p>
          </list-item>
        </list>
        <p>
<bold>Neurology</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Sensory neuropathy</p>
          </list-item>
          <list-item>
            <p>Taste disturbance</p>
          </list-item>
        </list>
        <p>
<bold>Dermatology</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Alopecia</p>
          </list-item>
          <list-item>
            <p>Rash</p>
          </list-item>
        </list>
        <p>
<bold>Drug Interactions </bold>
</p>
        <p>Patients who receive frequent chemotherapy infusions may use non-steroidal anti-inflammatories for pain control management. Clinicians should avoid administering ibuprofen to patients receiving pemetrexed. Both medications are eliminated renally. Pemetrexed is&#x000a0;a&#x000a0;substrate for organic anion transporter 3 (OAT3), and ibuprofen is an&#x000a0;organic anion transporter 3 (OAT3) inhibitor. Concomitant use may increase the risk of nephrotoxicity, myelosuppression, and gastrointestinal toxicity. In patients with a creatinine clearance between 45 mL/min and 79 mL/min, it is recommended to avoid ibuprofen 2 days before the first dose of pemetrexed and up to 2 days after the final&#x000a0;dose in a cycle.</p>
        <p>When&#x000a0;administered concurrently with nephrotoxic medications, there is a risk of prolonging the clearance time for pemetrexed. Simultaneous administration of other renally-eliminated substances may lead to a delay in clearance.<xref ref-type="bibr" rid="article-167918.r21">[21]</xref></p>
      </sec>
      <sec id="article-167918.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Pemetrexed is contraindicated in patients with a history of severe hypersensitivity reactions.&#x000a0;</p>
        <p>
<bold>Box Warning and Precautions</bold>
</p>
        <p>Use caution in patients with a history of&#x000a0;Stevens-Johnson syndrome or toxic epidermal necrolysis.<xref ref-type="bibr" rid="article-167918.r32">[32]</xref> Pemetrexed should be used with caution in patients with pre-existing bone marrow suppression due to reported cases of severe myelosuppression. This&#x000a0;medication&#x000a0;may also cause nephrotoxicity, which may lead to renal failure. In patients with a history of pulmonary disease, severe interstitial pneumonitis has been reported. Other precautions for pemetrexed are radiation recall, teratogenicity, live vaccines, and increased risk of toxicity with ibuprofen.<xref ref-type="bibr" rid="article-167918.r21">[21]</xref><xref ref-type="bibr" rid="article-167918.r33">[33]</xref></p>
      </sec>
      <sec id="article-167918.s6" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients receiving pemetrexed should be monitored with a complete blood count (CBC) with differential at day 1, 8, and 15 of each cycle. Female patients should be tested for pregnancy due to teratogenic properties. Before each cycle,&#x000a0;baseline laboratory testing using renal function tests such as serum creatinine, creatinine clearance, blood urea nitrogen and total bilirubin, aspartate transaminase, and alanine transaminase should be obtained.&#x000a0;Patients should also be monitored for adverse effects such as mucositis, pulmonary toxicity, dermatologic toxicity, and radiation recall. Pemetrexed should not be administered to patients with an absolute neutrophil count &#x0003c;1500 cells/mm<sup>3</sup>&#x000a0;or platelet count &#x0003c;100,000 cells/mm<sup>3</sup>. For nonhematologic toxicity grade 3 and above, pemetrexed should be held until the&#x000a0;patient's CBC&#x000a0;returns to baseline.<xref ref-type="bibr" rid="article-167918.r29">[29]</xref></p>
      </sec>
      <sec id="article-167918.s7" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Currently, no specific drugs are approved for the treatment of pemetrexed overdose. However, the data from animal studies suggests leucovorin may help alleviate the toxic effects associated with pemetrexed overdose. Symptoms of overdose include severe leukopenia, neutropenia (grade 4 lasting&#x000a0;3 days or more), and thrombocytopenia (grade 4). Additionally, leucovorin can be administered for bleeding associated with grade 3 thrombocytopenia and for managing grade 3 or 4 mucositis.<xref ref-type="bibr" rid="article-167918.r34">[34]</xref></p>
      </sec>
      <sec id="article-167918.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The collaborative efforts of healthcare professionals in managing patients&#x000a0;receiving pemetrexed&#x000a0;are crucial for optimizing patient outcomes and ensuring the highest quality of care. Each healthcare team member plays a unique role in the care continuum, contributing their expertise to provide comprehensive support to patients and their families. Effective communication among team members&#x000a0;promotes patient-centered care and facilitates seamless care coordination. Healthcare professionals can ensure patients receive the most appropriate and effective treatment while addressing their needs and preferences.</p>
        <p>As frontline caregivers, nurses are pivotal in administering chemotherapy, monitoring patients for adverse reactions, and providing essential education and support throughout treatment. Their close interaction with patients positions them to identify signs and symptoms early, enabling timely intervention and improving patient safety.</p>
        <p>With their specialized knowledge of medications and drug interactions, pharmacists are invaluable in optimizing medication regimens, minimizing adverse effects, and ensuring medication safety. Their collaboration with other healthcare professionals enhances the quality of care and contributes to better treatment outcomes.</p>
        <p>Ethical considerations, such as informed consent and patient autonomy, must guide decision-making processes to uphold patients' rights and promote shared decision-making. Respecting patients' choices and preferences fosters trust and collaboration between healthcare professionals and patients, ultimately leading to better treatment adherence and outcomes.</p>
        <p>Overall, multidisciplinary care guided by evidence-based practices, ethical principles, and effective communication is the cornerstone of successful cancer management with pemetrexed.</p>
      </sec>
      <sec id="article-167918.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=167918&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=167918">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/167918/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=167918">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-167918.s10">
        <title>References</title>
        <ref id="article-167918.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vergote</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Calvert</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kania</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kaiser</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zimmermann</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Sehouli</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer.</article-title>
            <source>Eur J Cancer</source>
            <year>2009</year>
            <month>May</month>
            <volume>45</volume>
            <issue>8</issue>
            <fpage>1415</fpage>
            <page-range>1415-23</page-range>
            <pub-id pub-id-type="pmid">19168349</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167918.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vogelzang</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Rusthoven</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Symanowski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Denham</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kaukel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ruffie</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gatzemeier</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Emri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Manegold</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Niyikiza</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Paoletti</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.</article-title>
            <source>J Clin Oncol</source>
            <year>2003</year>
            <month>Jul</month>
            <day>15</day>
            <volume>21</volume>
            <issue>14</issue>
            <fpage>2636</fpage>
            <page-range>2636-44</page-range>
            <pub-id pub-id-type="pmid">12860938</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167918.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chattopadhyay</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moran</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>ID</given-names>
              </name>
            </person-group>
            <article-title>Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications.</article-title>
            <source>Mol Cancer Ther</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>404</fpage>
            <page-range>404-17</page-range>
            <pub-id pub-id-type="pmid">17308042</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167918.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taylor</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Kuhnt</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Shih</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rinzel</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Grindey</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Barredo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jannatipour</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moran</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase.</article-title>
            <source>J Med Chem</source>
            <year>1992</year>
            <month>Nov</month>
            <day>13</day>
            <volume>35</volume>
            <issue>23</issue>
            <fpage>4450</fpage>
            <page-range>4450-4</page-range>
            <pub-id pub-id-type="pmid">1447744</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167918.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ceresoli</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Zucali</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Favaretto</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Grossi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bidoli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Del Conte</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ceribelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bearz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Morenghi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cavina</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Marangolo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Parra</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Santoro</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.</article-title>
            <source>J Clin Oncol</source>
            <year>2006</year>
            <month>Mar</month>
            <day>20</day>
            <volume>24</volume>
            <issue>9</issue>
            <fpage>1443</fpage>
            <page-range>1443-8</page-range>
            <pub-id pub-id-type="pmid">16549838</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167918.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ceresoli</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Zucali</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Mencoboni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Botta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grossi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cortinovis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zilembo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ripa</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tiseo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Favaretto</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Soto-Parra</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>De Vincenzo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bruzzone</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lorenzi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gianoncelli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ercoli</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Giordano</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Santoro</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma.</article-title>
            <source>Br J Cancer</source>
            <year>2013</year>
            <month>Aug</month>
            <day>06</day>
            <volume>109</volume>
            <issue>3</issue>
            <fpage>552</fpage>
            <page-range>552-8</page-range>
            <pub-id pub-id-type="pmid">23860535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167918.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Santoro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Stahel</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Nackaerts</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Baas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Karthaus</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Eberhardt</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Paz-Ares</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sundstrom</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ripoche</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Blatter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Visseren-Grul</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Manegold</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemona&#x000ef;ve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.</article-title>
            <source>J Thorac Oncol</source>
            <year>2008</year>
            <month>Jul</month>
            <volume>3</volume>
            <issue>7</issue>
            <fpage>756</fpage>
            <page-range>756-63</page-range>
            <pub-id pub-id-type="pmid">18594322</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167918.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kreuter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vansteenkiste</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Eberhardt</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zabeck</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kollmeier</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Serke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Frickhofen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Reck</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Engel-Riedel</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Neumann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thomeer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schumann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>De Leyn</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Graeter</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Stamatis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zuna</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Griesinger</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>M</given-names>
              </name>
              <collab>TREAT investigators</collab>
            </person-group>
            <article-title>Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study.</article-title>
            <source>Ann Oncol</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>986</fpage>
            <page-range>986-92</page-range>
            <pub-id pub-id-type="pmid">23161898</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167918.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choy</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gerber</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Bradley</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Iyengar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Monberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Treat</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Govindan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Koustensis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Obasaju</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: a systematic review of completed and ongoing studies.</article-title>
            <source>Lung Cancer</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>87</volume>
            <issue>3</issue>
            <fpage>232</fpage>
            <page-range>232-40</page-range>
            <pub-id pub-id-type="pmid">25650301</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167918.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scagliotti</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Parikh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>von Pawel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Biesma</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Vansteenkiste</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Manegold</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Serwatowski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gatzemeier</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Digumarti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zukin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Mellemgaard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Patil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rolski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Goksel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>de Marinis</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Simms</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sugarman</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Gandara</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.</article-title>
            <source>J Clin Oncol</source>
            <year>2008</year>
            <month>Jul</month>
            <day>20</day>
            <volume>26</volume>
            <issue>21</issue>
            <fpage>3543</fpage>
            <page-range>3543-51</page-range>
            <pub-id pub-id-type="pmid">18506025</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167918.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karayama</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Inui</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kuroishi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yokomura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Toyoshima</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shirai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Masuda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yamada</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yasuda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Suda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chida</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-na&#x000ef;ve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.</article-title>
            <source>Cancer Chemother Pharmacol</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>72</volume>
            <issue>2</issue>
            <fpage>445</fpage>
            <page-range>445-52</page-range>
            <pub-id pub-id-type="pmid">23807323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167918.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sweeney</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Kabbinavar</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>Vaughn</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Arning</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Curiel</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Obasaju</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nicol</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.</article-title>
            <source>J Clin Oncol</source>
            <year>2006</year>
            <month>Jul</month>
            <day>20</day>
            <volume>24</volume>
            <issue>21</issue>
            <fpage>3451</fpage>
            <page-range>3451-7</page-range>
            <pub-id pub-id-type="pmid">16849761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167918.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Phase I study of gemcitabine-cisplatin versus pemetrexed cisplatin for patients with advanced or metastatic bladder cancer.</article-title>
            <source>J BUON</source>
            <year>2018</year>
            <season>Mar-Apr</season>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>475</fpage>
            <page-range>475-481</page-range>
            <pub-id pub-id-type="pmid">29745095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167918.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Spielmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Namer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>duBois</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Unger</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dodwell</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vodvarka</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lind</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Calvert</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Casado</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zelek</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lluch</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carrasco</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kayitalire</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zielinski</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines.</article-title>
            <source>Ann Oncol</source>
            <year>2003</year>
            <month>Aug</month>
            <volume>14</volume>
            <issue>8</issue>
            <fpage>1246</fpage>
            <page-range>1246-52</page-range>
            <pub-id pub-id-type="pmid">12881387</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167918.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Llombart-Cussac</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Harbeck</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Anghel</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Eniu</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Verrill</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Neven</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>De Gr&#x000e8;ve</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Melemed</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Simms</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kaiser</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer.</article-title>
            <source>Clin Cancer Res</source>
            <year>2007</year>
            <month>Jun</month>
            <day>15</day>
            <volume>13</volume>
            <issue>12</issue>
            <fpage>3652</fpage>
            <page-range>3652-9</page-range>
            <pub-id pub-id-type="pmid">17575230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167918.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lorusso</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ferrandina</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pignata</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ludovisi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vigan&#x000f2;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Scalone</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Scollo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Breda</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pietragalla</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Scambia</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group.</article-title>
            <source>Ann Oncol</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>61</fpage>
            <page-range>61-6</page-range>
            <pub-id pub-id-type="pmid">19605508</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167918.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Padda</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Riess</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>West</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Neal</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Wakelee</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>Pemetrexed in patients with thymic malignancies previously treated with chemotherapy.</article-title>
            <source>Lung Cancer</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>87</volume>
            <issue>1</issue>
            <fpage>34</fpage>
            <page-range>34-8</page-range>
            <pub-id pub-id-type="pmid">25443273</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167918.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gbolahan</surname>
                <given-names>OB</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Salter</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Yiannoutsos</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Burns</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chiorean</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Loehrer</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>A Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic Carcinoma.</article-title>
            <source>J Thorac Oncol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>13</volume>
            <issue>12</issue>
            <fpage>1940</fpage>
            <page-range>1940-1948</page-range>
            <pub-id pub-id-type="pmid">30121390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167918.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldman</surname>
                <given-names>ID</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Molecular, biochemical, and cellular pharmacology of pemetrexed.</article-title>
            <source>Semin Oncol</source>
            <year>2002</year>
            <month>Dec</month>
            <volume>29</volume>
            <issue>6 Suppl 18</issue>
            <fpage>3</fpage>
            <page-range>3-17</page-range>
            <pub-id pub-id-type="pmid">12571805</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167918.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ouellet</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Periclou</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Woodworth</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Lalonde</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer.</article-title>
            <source>Cancer Chemother Pharmacol</source>
            <year>2000</year>
            <volume>46</volume>
            <issue>3</issue>
            <fpage>227</fpage>
            <page-range>227-34</page-range>
            <pub-id pub-id-type="pmid">11021740</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167918.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Posada</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Bacon</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Schneck</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Tirona</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Higgins</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Pak</surname>
                <given-names>YA</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Hillgren</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Prediction of renal transporter mediated drug-drug interactions for pemetrexed using physiologically based pharmacokinetic modeling.</article-title>
            <source>Drug Metab Dispos</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>325</fpage>
            <page-range>325-34</page-range>
            <pub-id pub-id-type="pmid">25504564</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167918.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Baldi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Muthu</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Prasad</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Behera</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kapoor</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Timing of folic acid/vitamin B12 supplementation and hematologic toxicity during first-line treatment of patients with nonsquamous non-small cell lung cancer using pemetrexed-based chemotherapy: The PEMVITASTART randomized trial.</article-title>
            <source>Cancer</source>
            <year>2019</year>
            <month>Jul</month>
            <day>01</day>
            <volume>125</volume>
            <issue>13</issue>
            <fpage>2203</fpage>
            <page-range>2203-2212</page-range>
            <pub-id pub-id-type="pmid">30825389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167918.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clarke</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Abratt</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Goedhals</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Millward</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Ackland</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-na&#x000ef;ve patients with advanced non-small-cell lung cancer.</article-title>
            <source>Ann Oncol</source>
            <year>2002</year>
            <month>May</month>
            <volume>13</volume>
            <issue>5</issue>
            <fpage>737</fpage>
            <page-range>737-41</page-range>
            <pub-id pub-id-type="pmid">12075742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167918.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rusch</surname>
                <given-names>VW</given-names>
              </name>
            </person-group>
            <article-title>Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care?</article-title>
            <source>J Clin Oncol</source>
            <year>2003</year>
            <month>Jul</month>
            <day>15</day>
            <volume>21</volume>
            <issue>14</issue>
            <fpage>2629</fpage>
            <page-range>2629-30</page-range>
            <pub-id pub-id-type="pmid">12860935</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167918.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hill</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vargo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Streeter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Carbone</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>Safety of dose-reduced pemetrexed in patients with renal insufficiency.</article-title>
            <source>J Oncol Pharm Pract</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>25</volume>
            <issue>5</issue>
            <fpage>1125</fpage>
            <page-range>1125-1129</page-range>
            <pub-id pub-id-type="pmid">29871545</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167918.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mita</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Sweeney</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Goetz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hammond</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Patnaik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tolcher</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Villalona-Calero</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sandler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chaudhuri</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Molpus</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Latz</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Simms</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chaudhary</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Rowinsky</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Takimoto</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.</article-title>
            <source>J Clin Oncol</source>
            <year>2006</year>
            <month>Feb</month>
            <day>01</day>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>552</fpage>
            <page-range>552-62</page-range>
            <pub-id pub-id-type="pmid">16391300</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167918.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Rouw</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Croes</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Posthuma</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Agterhuis</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Schoenmaekers</surname>
                <given-names>JJAO</given-names>
              </name>
              <name>
                <surname>Derijks</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Burger</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Dingemans</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ter Heine</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetically-guided dosing of pemetrexed in a patient with renal impairment and a patient requiring hemodialysis.</article-title>
            <source>Lung Cancer</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>130</volume>
            <fpage>156</fpage>
            <page-range>156-158</page-range>
            <pub-id pub-id-type="pmid">30885337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167918.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garassino</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Gadgeel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Speranza</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Felip</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Esteban</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>D&#x000f3;mine</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hochmair</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Bischoff</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Peled</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Grossi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jennens</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Reck</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hui</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Garon</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Kurata</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Schwarzenberger</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pietanza</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez-Abreu</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.</article-title>
            <source>J Clin Oncol</source>
            <year>2023</year>
            <month>Apr</month>
            <day>10</day>
            <volume>41</volume>
            <issue>11</issue>
            <fpage>1992</fpage>
            <page-range>1992-1998</page-range>
            <pub-id pub-id-type="pmid">36809080</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167918.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adjei</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Pharmacology and mechanism of action of pemetrexed.</article-title>
            <source>Clin Lung Cancer</source>
            <year>2004</year>
            <month>Apr</month>
            <volume>5 Suppl 2</volume>
            <fpage>S51</fpage>
            <page-range>S51-5</page-range>
            <pub-id pub-id-type="pmid">15117425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167918.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paz-Ares</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>de Marinis</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dediu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pujol</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Bidoli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Molinier</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Sahoo</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Laack</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Reck</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Corral</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Melemed</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>John</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Chouaki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zimmermann</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Visseren-Grul</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gridelli</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>247</fpage>
            <page-range>247-55</page-range>
            <pub-id pub-id-type="pmid">22341744</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167918.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hanna</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Shepherd</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Fossella</surname>
                <given-names>FV</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>De Marinis</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>von Pawel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gatzemeier</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Tsao</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Pless</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Muller</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Desch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Szondy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gervais</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shaharyar</surname>
              </name>
              <name>
                <surname>Manegold</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Paoletti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Einhorn</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bunn</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.</article-title>
            <source>J Clin Oncol</source>
            <year>2004</year>
            <month>May</month>
            <day>01</day>
            <volume>22</volume>
            <issue>9</issue>
            <fpage>1589</fpage>
            <page-range>1589-97</page-range>
            <pub-id pub-id-type="pmid">15117980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167918.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pierard-Franchimont</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lesuisse</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Humbert</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Delvenne</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pierard</surname>
                <given-names>GE</given-names>
              </name>
            </person-group>
            <article-title>Toxic epidermal necrolysis and antifolate drugs in cancer chemotherapy.</article-title>
            <source>Curr Drug Saf</source>
            <year>2012</year>
            <month>Nov</month>
            <day>01</day>
            <volume>7</volume>
            <issue>5</issue>
            <fpage>357</fpage>
            <page-range>357-60</page-range>
            <pub-id pub-id-type="pmid">23373549</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167918.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>HY</given-names>
              </name>
            </person-group>
            <article-title>Interstitial Pneumonitis after Treatment with Pemetrexed for Non-small Cell Lung Cancer.</article-title>
            <source>Cancer Res Treat</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>45</volume>
            <issue>1</issue>
            <fpage>74</fpage>
            <page-range>74-7</page-range>
            <pub-id pub-id-type="pmid">23613674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167918.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gridelli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kaukel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gregorc</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Migliorino</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Manegold</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Favaretto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martoni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Caffo</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Schmittel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;oz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reck</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial.</article-title>
            <source>J Thorac Oncol</source>
            <year>2007</year>
            <month>Mar</month>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>221</fpage>
            <page-range>221-9</page-range>
            <pub-id pub-id-type="pmid">17410045</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
